A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (VOYAGE)
Phase 3
Recruiting
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Other: PlaceboDrug: MM120 (LSD D-Tartrate)
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Mind Medicine, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06741228
- Locations
- 🇺🇸
Lighthouse Psychiatry, Gilbert, Arizona, United States
🇺🇸Kadima Neuropsychiatry Institute, La Jolla, California, United States
🇺🇸UCSF Department of Neurology, San Francisco, California, United States
A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
Phase 2
Completed
- Conditions
- Anxiety Generalized
- Interventions
- Other: PlaceboDrug: MM-120 (LSD D-Tartrate)
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Mind Medicine, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT05407064
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸Lutheran Hospital - Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸iResearch Atlanta, Decatur, Georgia, United States
Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial
Phase 2
Completed
- Conditions
- Attention Deficit DisorderADHD
- Interventions
- Drug: MM-120Other: Placebo
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Mind Medicine, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT05200936
- Locations
- 🇳🇱
Maastricht University, Maastricht, Netherlands
🇨🇭University Hospital Basel, Basel, Switzerland
A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Addiction
- Interventions
- Drug: 18-MC Compound
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Mind Medicine, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04292197
- Locations
- 🇦🇺
Dr. Sam Salman, Perth, Australia
© Copyright 2025. All Rights Reserved by MedPath